Infanrix Vaccine Description - 2022
Infanrix is a vaccine indicated for active immunization against diphtheria, tetanus, and pertussis as a 5-dose series in infants and children aged 6 weeks. Infanrix active ingredients are non-infectious substances from tetanus, diphtheria bacteria, and purified proteins of pertussis bacteria. Each 0.5 mL dose contains 30 IU (25 Lf U) of diphtheria toxoid.
Infanrix Vaccine Indication
Infanrix is a vaccine indicated for active immunization against diphtheria, tetanus, and pertussis as a 5-dose series in infants and children 6 weeks to 7 years of age (prior to the seventh birthday).
Infanrix Vaccine Dosage
Infanrix is approved for intramuscular administration in infants and children 6 weeks to 7 years of age (prior to the seventh birthday) as a 5-dose series. A primary immunization course of 3 doses administered at 2, 4, and 6 months of age (at intervals of 4 to 8 weeks). The first dose may be given as early as 6 weeks of age. Followed by 2 booster doses, administered at 15 to 20 months of age and at 4 to 6 years of age.
Preferred administration site: Anterolateral aspect of the thigh for most infants younger than 12 months of age. Deltoid muscle of the upper arm for most children 12 months of age to 7 years of age.
Infanrix Vaccine News - 2022
February 21, 2022 - The UK Health Agency published the 2022 routine immunization schedule. This publication included immunization programs as well as additional vaccines for individuals with underlying medical conditions.
February 9, 2022 - GSK reported sales of DTPa-containing vaccines (Infanrix, Pediarix, and Boostrix) decreased 4% AER but grew 1% CER. Infanrix/Pediarix sales decreased 14% AER, 9% CER to £543 million, reflecting lower tender volume in Europe and International as well as a change in recommendation for the dosing schedule in Germany, partly offset by increased demand in the US. Boostrix sales grew 9% AER, 14% CER to £521 million, largely driven by demand recovery and tender volumes in International, as well as higher demand and share in the US.
October 31, 2019 - GSK Korea announced its newly launched Infanrix IPV-Hib, a quintuplet vaccine that covers diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae type b (Hib). The company hopes that by adding efficiency to the excellence of the existing Infanrix brand, it can become a vaccine that leads to the prevention of disease for infants and toddlers, said Professor Lee Jin of the Department of Pediatrics at Hanil Hospital.
Infanrix Vaccine Clinical Trials
Infanrix has been tested in over 140 clinical trials. They can be found at this link.